WO2006004226A1 - Compositions for cancer prevention, treatment, or amelioration comprising papaya extract - Google Patents
Compositions for cancer prevention, treatment, or amelioration comprising papaya extract Download PDFInfo
- Publication number
- WO2006004226A1 WO2006004226A1 PCT/JP2005/012880 JP2005012880W WO2006004226A1 WO 2006004226 A1 WO2006004226 A1 WO 2006004226A1 JP 2005012880 W JP2005012880 W JP 2005012880W WO 2006004226 A1 WO2006004226 A1 WO 2006004226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- papaya
- cancer
- composition
- leaves
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present invention relates to compositions or food compositions for cancer prevention, treatment, or improvement. More specifically, it relates to compositions or food compositions that comprise, as an active ingredient, components extracted by brewing leaves or other parts of the papaya plant
- Carlca papaya ⁇ Carlca papaya
- chemotherapeutic agents including cyclophosphamide, busulfan and other alkylating agents; methotrexate, 5-fluorouracil and other agents that inhibit nucleic acid synthesis; and actinomycin D, daunomycin and other antibiotics.
- chemotherapeutic agents include cyclophosphamide, busulfan and other alkylating agents; methotrexate, 5-fluorouracil and other agents that inhibit nucleic acid synthesis; and actinomycin D, daunomycin and other antibiotics.
- chemotherapeutic agents include cyclophosphamide, busulfan and other alkylating agents; methotrexate, 5-fluorouracil and other agents that inhibit nucleic acid synthesis; and actinomycin D, daunomycin and other antibiotics.
- chemotherapeutic agents include cyclophosphamide, busulfan and other alkylating agents; methotrexate, 5-fluorouracil and other agents that inhibit nucleic
- the objective of the present invention is to provide compositions or food compositions for cancer prevention, treatment, or improvement that are highly effective in the treatment and prevention of cancer, and yet have few side effects and a high level of safety.
- the present inventors discovered that components of papaya, preferably one or more extracted papaya components obtained by brewing papaya, have superior effects in the treatment of cancer, and that accordingly, they can become compositions or food compositions for cancer prevention, treatment, or improvement with few side effects and a high level of safety, thus completing the present invention. Accordingly, the present invention relates to compositions or food compositions for cancer prevention, treatment, or improvement that comprise as active ingredients one or more components of the papaya plant ⁇ Carica papaya) , and preferably one or more components extracted by brewing a part of a papaya plant.
- the present invention uses components of the papaya plant (Carica papaya) , preferably components extracted by brewing a part of a papaya plant tissue, as active ingredients.
- the tissue of the papaya plant may be any of its leaves, roots, stems or fruit, but the leaves are particularly preferable.
- this papaya tissue is dried, and the dried material thus obtained is added to cold water or boiling water, brewed for a long time, and the brew thus obtained is used as an active ingredient.
- the leaves may be added to cold water or boiling water and brewed. More specifically, papaya leaves, for example, may be left in the sun, normally for one or two days, and dried to obtain the dried material.
- One to several of these dried leaves are added to cold water or boiling water (normally 400 ml to 3000 ml) , and preferably 500 ml to 1000 ml, and brewed for normally two hours to 15 hours, and preferably three hours to 12 hours.
- the vessel used for brewing is preferably not a metal vessel, but rather a glass, wooden, plastic or other vessel.
- a component thus obtained comprises the effect of suppressing the proliferation of cancer cells, and can be used as it is as an active ingredient of the composition or food composition according to the present invention.
- the composition can also be provided as a botanical drug. According to the present invention, this brew may be further subjected to a refining process.
- the components that comprise the effect of suppressing the proliferation of cancer cells can be fractionated, and the fractionated components thus obtained may be used as an active ingredient.
- Such fractionated components are, for example, preferably obtained from an extract of papaya leaves that, when subjected to gel filtration chromatography using a gel filtration column filled with cross-linked polyvinyl alcohol gel, the gel filtration column having an exclusion limit molecular weight of 40,000 when pullulan is used as a sample, is eluted in a portion of the eluate equivalent to 50-70 vol.% of the volume of the column.
- the column used for gel filtration chromatography may be a column that is a stainless-steel tube with an inside diameter of 7.6 mm x length of 500 mm, filled with cross-linked polyvinyl alcohol gel with a grain diameter of 9 ⁇ m, and having an exclusion limit molecular weight of 40, 000 when pullulan is used as a sample (Shodex Asahipak GS-310 7G) (Showa Denko K. K.) .
- a neutral buffer solution for example a phosphate buffer solution, may be used as the eluate.
- a specific example is obtained by dissolving 9.6 g of powdered Dulbecco's PBS (-) "Nissui” (Nihon Pharmaceutical Co., Ltd.) in 1 L of deionized water and autoclaving for 15 minutes at 121°C to obtain a sterilized buffer solution (pH 7.3 to 7.65) .
- Components with molecular weights of 1700, 1000, 700, 600, 400, and 300 were detected by an RI detector. Peaks were detected for molecules (groups) at molecular weights of 1700 and 1000 under UV (260 run) , and were also found at low molecular weights (300 to 700) , also under UV (260 nm) .
- the fractionated components comprising anti-tumor effects further refined from the extract of papaya leaves are contained within molecules (groups) with molecular weights of 1700, 1000 and 700 to 300 that absorb UV (260 nm) , and the molecule (groups) with molecular weights of 1700, 1000, 700, 600, 400, 300 and 200 that are detectable by RI, each of which are thought to act independently or in combination to achieve the anti-tumor effect.
- the brews/extracts thus obtained or further fractionated components maybe ingested as they arein order to prevent, treat, or ameliorate cancer.
- the brews/extracts or fractionated components may also be mixed with appropriate ingredients ordinarily used in drinks and taken as a drink.
- the brews/extracts or fractionated components may be dried if necessary, and then taken in a powder or tablet or other form after the addition of excipients or other additives ordinarily used in powders, tablets or the like.
- the papaya components of brews/extracts, or fractionated components thereof are preferably stored not in a metal vessel, but rather in a glass, wooden, plastic or other vessel under low-temperature conditions, for example around 4 0 C.
- the present invention's brew/extract components, prepared from, for example, a papaya leaf, or fractionated components thereof, are effective in the prevention or treatment of stomach cancer, lung cancer, pancreatic cancer, liver cancer, colon cancer, uterine cancer, ovarian cancer, neuroblastoma or other solid cancers, or lymphoma, leukemia or otherblood cancers.
- treatment is administered to those suffering from a disease.
- treatment is administered as prophylaxis.
- the dose of the brew/extract components or fractionated components thereof to be administered will depend on the dosage form, symptoms of the subject, type of cancer or the like. However, for example, when the brew/extract is taken, it is normally preferable to take an amount of 100 ml to 750 ml per day, every day for between one month and three months. When the fractionated components are taken, it is preferable to take an amount of 10 ml to 200 ml per day, every day for between one month and three months.
- the present invention provides food compositions that comprise a papaya ⁇ Carica papaya) brew/extract as an effective ingredient for preventing or treating cancer.
- a food composition of the present invention may include, for example, a health food, a functional food, a specified health food, a nutrient supplement, an enteral nutrient, and the like, but is not limited to these foods so long as it is effective in preventing or ameliorating cancer.
- ⁇ Carica papaya) brew/extract component can be combined with an additive acceptable in view of food sanitation, andprocessedto make a general food, a health food, a functional food, a specified health food, a nutrient supplement, an enteral nutrient, etc.
- an additive such as a stabilizer, preservative, colorant, perfume, vitamin can be appropriately added to a papaya ⁇ Carica papaya) brew/extract component, mixed, and processed by standard methods into a form suitable for a food composition, such as a tablet, pill, granule, powder, capsule, liquid, cream, drink, etc.
- the food compositions of the present invention include those sold with a description or indication written on the food composition' s packaging container and/or in a promotional pamphlet, to the effect that the food composition, and/or an ingredient in the food composition, comprises the effect of preventing, or ameliorating cancer.
- FIG. 1 depicts graphs showing the anti-tumor effect of a papaya leaf extract according to the present invention on AGS
- stomach cancer cell line 1000 cells/well and 2000 cells/well, cultured for three days
- FIG. 2 depicts graphs showing the anti-tumor effect of the papaya leaf extract according to the present invention on
- Capan-1 (a pancreatic cancer cell line: 1000 cells/well and 2000 cells/well, cultured for five days; 40000 cells/well, cultured for four days) .
- FIG. 3 is a graph showing the anti-tumor effect of the papaya leaf extract according to the present invention on DLD-I
- a colon cancer cell line 20000 cells/well, cultured for four days.
- FIG. 4 is a graph showing the anti-tumor effect of the papaya leaf extract according to the present invention on DOV-13 (ovarian cancer cell line: 3000 cells/well, cultured for two days) .
- FIG. 5 is a graph showing the anti-tumor effect of a
- FIG. 6 depicts graphs showing the anti-tumor effect of the papaya leaf extract according to the present invention on
- MCF-7 breast cancer cell line: 2500 cells/well and 7500 cells/well, cultured for six days.
- FIG. 7 depicts graphs showing the anti-tumor effect of the papaya leaf extract according to the present invention on
- T98G (a neuroblastoma cell line: 2000 cells/well and 4000 cells/well, cultured for three days) .
- FIG. 8 is a graph showing the proliferation suppression effect of the papaya leaf extract according to the present invention on HeIa (a uterine cancer cell line) .
- FIG. 9 depicts graphs showing the proliferation suppression effect of the papaya leaf extract according to the present invention on Karpas (a lymphoma cell line) .
- FIG. 10 depicts graphs showing the proliferation suppression effect of the papaya leaf extract according to the present invention on CD26 negative Jurkat (T cell leukemia cell line) .
- FIG. 11 depicts graphs showing the proliferation suppression effect of the papaya leaf extract according to the present invention on CD26 positive Jurkat (T cell leukemia cell line) .
- FIG.12 shows the results ofmeasurement of the suppression effect of Jurkat T cell proliferation by components of papaya leaf extract fractionated by gel filtration chromatography.
- Papaya leaves were left in the air for approximately one to two days under the sun and thus dried, and approximately 27 g, that is, about one dried papaya leaf, was added to 500 ml of water in a glass vessel, brewed for twelve hours, until the total quantity was 50 ml.
- the brew thus obtained was filter-sterilized to obtain the papaya extract according to the present invention.
- Method Cancer cells from the AGS (stomach cancer cell line), Capan-1 (pancreatic cancer cell line) , DLD-I (colon cancer cell line) , Dov-13 (ovarian cancer cell line) , Karpas (lymphoma cell line) , MCF-7 (breast cancer cell line) and T98G (neuroblastoma cell line) were dispensed into a 96-well microtiter plate and cultured in a RPMI-I640 solution medium containing 10% fetal calf serum, and cultured until confluent.
- the papaya leaf extract prepared according to Working Example 1 was diluted with culture medium by 20 times (1:20), 150 times (1:150) and 400 times (1:400) respectively, and a volume of 100 ⁇ l of the dilute solution was added to the cancer cell lines in each well, which were cultured at 37°C for two to eight days. Thereafter, 25 ⁇ l of 3- (4, 5-dimethylthiazole-2-yl) 2, 5-diphenyl tetrazolium bromide (MTT) was added to each well to make the final concentration 1 mg/ml, and they were cultured at 37°C for an additional two hours, and then 100 ⁇ l of isopropanol containing 0.04 N hydrochloric acid was added. After culturing overnight at 37 0 C, the absorbance at 570 nm was measured and compared against that of the control to examine just how many of the cells were killed by the papaya leaf extract. (2) Results
- the papaya leaf extract prepared according to Working Example 1 was diluted with culture medium (RPMI-1640 solution containing 10% fetal calf serum) to various dilution ratios, and 10 ⁇ l of each was added to the cancer cell lines in each well, which were cultured at 37 0 C in a 5% CO 2 incubator. After 24 and 48 hours of culturing, 3 H-thymidine was added in the amount of 1 ⁇ Ci (1 microcurie) /10 ⁇ l. After four hours, the amount of 3 H-thymidine (cpm) incorporated into the cancer cells for the purpose of DNA synthesis was measured with a scintillation counter to examine the effect of suppressing the proliferation of cancer cells.
- culture medium RPMI-1640 solution containing 10% fetal calf serum
- the pancreatic metastasis of the stomach cancer disappeared, the CEA level dropped to 2.3, and the alpha fetoprotein also dropped to 2.0, with no relapse found thereafter.
- Dried papaya leaf (approximately 27 g) was heated for one hour to 100 0 C in 500 ml of distilled water using a glass beaker, and then further heated for ten hours at 55°C to prepare an extract concentrated to a volume of 50 ml. Thereafter, fractionation by molecular weight was performed by gel filtration chromatography, and further analysis of the anti-tumor active substances was performed.
- the column used for gel filtration chromatography was a column that is a stainless-steel tube with an inside diameter of 7.6 mm x length of 500 mm, filled with cross-linked polyvinyl alcohol gel (grain diameter of 9 ⁇ m) , and having a molecular weight exclusion limit of 40,000 when pullulan is used as a sample (Shodex Asahipak GS-3107G) (Showa Denko K. K. ) .
- the eluate used was obtained by dissolving 9.6 g of powdered Dulbecco's PBS (-) "Nissui” (Nikon Pharmaceutical Co., Ltd.) in 1 L of deionized water, and autoclaving for 15 minutes at 121°C to obtain a sterilized buffer solution (pH 7.3 to 7.65) .
- 3 H-thymidine 3 H-TdR
- 3 H-TdR 3 H-thymidine
- FIG. 12 illustrates the effects of the addition of. fractionated components of papaya leaf infusion on the proliferation of Jurkat T cells.
- the Jurkat T cells cultured in medium, and Jurkat T cells to which a quantity of PBS equal to the fractionated components was added exhibited 3 H-TdR incorporation of 15192.33 ⁇ 413.4 (cpm) and 16837.33 ⁇ 288 (cpm) respectively.
- Jurkat T cells added with the fractionated components eluted between 12 minutes and 13 minutes of gel filtration chromatography elution time
- fraction 13 the portion of eluate equivalent to 53 to 57 vol.% of the column volume
- fraction 14 the portion of eluate equivalent to 57 to 62 vol.% of the column volume
- the present inventors found that the fractionated components of the papaya leaf extract that comprise the effect of suppressing the proliferation of Jurkat T cells (anti-tumor effect) are present in fractions 13 and 14.
- the fractionated components obtained by gel filtration chromatography that comprise anti-tumor effects were eachplaced in a similar column, and the chromatogram was measured with a differential refractometer (RI) (RID-6A) (Shimadzu Corp.) and ultraviolet spectrophotometer (SPD-IOAVp) (Shimadzu Corp.) .
- RI differential refractometer
- SPD-IOAVp ultraviolet spectrophotometer
- fraction 13 components with molecular weights of 1700, 1000, 700 and 300 were detectedby an RI detector, and peaks were also detected for molecules (groups) at molecular weights of 1700 and 1000 under UV (260 nm) .
- this fraction is presumed to contain compounds with absorption in these regions.
- components with molecular weights of 1700, 1000, 600, 400 and 200 were detected by the RI detector, and peaks were found for molecules (groups) at molecular weights of 1700 and 1000 and also at low molecular weights (300 to 700) under UV (260 nm) .
- the fractionated components comprising anti-tumor effects extracted from papaya leaves were extracted between 12 minutes and 14 minutes after the start of the gel filtration chromatography used in this experimental system.
- the components comprising anti-tumor effects are contained within the molecules (groups) with molecular weights of 1700,
- the components of an brew/extract of leaves or other parts of the papaya plant ⁇ Carica papaya) or fractionated components thereof, for example, are effective in the prevention or treatment of stomach cancer, lung cancer, pancreatic cancer, colon cancer or other solid cancers, or lymphoma, leukemia or other blood cancers, and are very safe with few side effects, making their medical significance extremely high.
- food compositions comprising a papaya plant ⁇ Carica papaya) extract component as an effective ingredient for the prevention or amelioration of cancer are highly expected to become functional foods contributing to the preservation and promotion of human health.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05760105A EP1778262A1 (en) | 2004-07-06 | 2005-07-06 | Compositions for cancer prevention, treatment, or amelioration comprising papaya extract |
US11/631,655 US20080069907A1 (en) | 2004-07-06 | 2005-07-06 | Compositions for Cancer Prevention, Treatment, or Amelioration Comprising Papaya Extract |
JP2007520020A JP2008505887A (en) | 2004-07-06 | 2005-07-06 | A composition for preventing, treating or ameliorating cancer comprising papaya extract |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58510104P | 2004-07-06 | 2004-07-06 | |
US60/585,101 | 2004-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006004226A1 true WO2006004226A1 (en) | 2006-01-12 |
Family
ID=35044631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/012880 WO2006004226A1 (en) | 2004-07-06 | 2005-07-06 | Compositions for cancer prevention, treatment, or amelioration comprising papaya extract |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080069907A1 (en) |
EP (1) | EP1778262A1 (en) |
JP (1) | JP2008505887A (en) |
WO (1) | WO2006004226A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2985182A1 (en) * | 2011-12-29 | 2013-07-05 | Gencix | COMPOSITION BASED ON PAPAYER LEAVES INHIBITING THE GROWTH OF BACTERIA IN ORAL SPHERE. |
EP2821106A1 (en) * | 2013-07-05 | 2015-01-07 | Cellquantum GmbH | Composition and use thereof for the treatment of tumor indications |
WO2021182647A1 (en) * | 2020-03-11 | 2021-09-16 | Songok Elijah | Fortification of foods with carica papaya seeds for treatment of schistosomiasis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103653238B (en) * | 2012-09-17 | 2015-12-02 | 福建中烟工业有限责任公司 | The application of papaya leaf extract in cigarette |
US9789144B2 (en) * | 2013-03-14 | 2017-10-17 | The Regents Of The University Of California | Inhibition of hypoxia-inducible factor activity with Carica papaya extracts |
JP2015038043A (en) * | 2013-08-19 | 2015-02-26 | 幾夫 森本 | Composition for immunity activation |
BR112021000310A2 (en) * | 2018-07-12 | 2021-06-29 | International Flavors & Fragrances Inc. | sweetness enhancement method of a sweetness modifier, composition, and consumer product |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3053595A (en) * | 1993-07-07 | 1995-11-09 | Gerard Amena | Therapeutic treatment and preparations |
US5468480A (en) * | 1989-04-28 | 1995-11-21 | The Boots Company Plc | Pharmaceutical composition of purified chymopapain |
JPH1036274A (en) * | 1996-07-22 | 1998-02-10 | Renkutetsuku Lab Kk | Metal salt mixture arising from papaya and its production |
EP1103579A1 (en) * | 1999-11-23 | 2001-05-30 | Societe Des Produits Nestle S.A. | A process for the extraction of lycopene |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2743809B1 (en) * | 1996-01-18 | 1998-04-10 | Pf Medicament | MACROCYCLIC ETHERS OF CARPAIN |
-
2005
- 2005-07-06 WO PCT/JP2005/012880 patent/WO2006004226A1/en active Application Filing
- 2005-07-06 EP EP05760105A patent/EP1778262A1/en not_active Withdrawn
- 2005-07-06 US US11/631,655 patent/US20080069907A1/en not_active Abandoned
- 2005-07-06 JP JP2007520020A patent/JP2008505887A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5468480A (en) * | 1989-04-28 | 1995-11-21 | The Boots Company Plc | Pharmaceutical composition of purified chymopapain |
AU3053595A (en) * | 1993-07-07 | 1995-11-09 | Gerard Amena | Therapeutic treatment and preparations |
JPH1036274A (en) * | 1996-07-22 | 1998-02-10 | Renkutetsuku Lab Kk | Metal salt mixture arising from papaya and its production |
EP1103579A1 (en) * | 1999-11-23 | 2001-05-30 | Societe Des Produits Nestle S.A. | A process for the extraction of lycopene |
Non-Patent Citations (5)
Title |
---|
ANONYMOUS: "Papaya beer", INTERNET ARTICLE, 7 May 2004 (2004-05-07), XP002348835, Retrieved from the Internet <URL:http://web.archive.org/web/20040517095843/http://rejoiceinlife.com/recipes/papayaBeer.php> [retrieved on 20051012] * |
DATABASE WPI Section Ch Week 199816, Derwent World Patents Index; Class B04, AN 1998-174830, XP002286898, "Metal salt mixture from papaya - prepared by extracting leaf, stem, petiole and rhizome of papaya, for oral use, as vitamin, drink, nutrition auxiliary agent or seasoning" * |
DAWSON E: "The medicinal properties of the papaya, Carica papaya L", ETHNOBOTANICAL LEAFLETS, 15 May 1998 (1998-05-15), XP002271935 * |
OLIVEROS-BELARDO L: "POSSIBLE ANTITUMOR CONSTITUENT OF CARICA PAPAYA", CHEMICAL ABSTRACTS + INDEXES, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, vol. 80, no. 7, 18 February 1974 (1974-02-18), pages 6, XP002042369, ISSN: 0009-2258 * |
See also references of EP1778262A1 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2985182A1 (en) * | 2011-12-29 | 2013-07-05 | Gencix | COMPOSITION BASED ON PAPAYER LEAVES INHIBITING THE GROWTH OF BACTERIA IN ORAL SPHERE. |
WO2013098413A3 (en) * | 2011-12-29 | 2014-08-07 | Esprit D'ethique | Composition that inhibits bacterial growth and use thereof |
EP2821106A1 (en) * | 2013-07-05 | 2015-01-07 | Cellquantum GmbH | Composition and use thereof for the treatment of tumor indications |
WO2015000947A1 (en) * | 2013-07-05 | 2015-01-08 | Cellquantum Gmbh | Composition and use thereof for the treatment of tumor indications |
WO2021182647A1 (en) * | 2020-03-11 | 2021-09-16 | Songok Elijah | Fortification of foods with carica papaya seeds for treatment of schistosomiasis |
Also Published As
Publication number | Publication date |
---|---|
EP1778262A1 (en) | 2007-05-02 |
US20080069907A1 (en) | 2008-03-20 |
JP2008505887A (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
US20080069907A1 (en) | Compositions for Cancer Prevention, Treatment, or Amelioration Comprising Papaya Extract | |
US10576057B2 (en) | Methods for treating muscle wasting and degeneration diseases | |
Khan et al. | Phytochemical and pharmacological properties on Citrus limetta (Mosambi) | |
KR101734979B1 (en) | Composition for preventing and treating cancer, and enhancing the immune action | |
ES2732247T3 (en) | Olive extract containing desramnosilacteósido | |
JP6293099B2 (en) | Use of ginsenoside F2 for prevention or treatment of liver diseases | |
JP2008214299A (en) | Composition for prevention, treatment, or amelioration of cancer containing water-soluble extract constituents of carica papaya and hedyotis diffusa | |
KR101439405B1 (en) | Composition for preventing or treating renal disease | |
KR20210052837A (en) | Pharmaceutical composition for preventing or treating cancer, comprising a Disocactus flagelliformis extract | |
KR101941183B1 (en) | Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof | |
KR20140016863A (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
KR20220119335A (en) | composition anticancer and inhibition of multidrug resistance comprising extract of Trichosanthes kirilowii Maxim, Dictamnus dasycarpus Turcz. and Morus alba L. | |
RU2408383C1 (en) | Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions) | |
KR101898891B1 (en) | Composition for Suppressing Side effects of Apoptosis-inducing Anti-cancer Drugs Using Ginsenoside Compound K | |
KR102119795B1 (en) | Anti-inflammatory Composition Comprising Broccoli Extract | |
CN113116940A (en) | Application of lactobacillus paracasei GMNL-346 for resisting oral cancer | |
KR20210147247A (en) | A composition for immune enhancement comprising narrow-leaf erecta fig extract mixture | |
KR100895500B1 (en) | Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient | |
JP6775226B2 (en) | Anti-cancer drug action enhancer and anti-cancer drug kit equipped with it | |
KR101739425B1 (en) | Composition for preventing or improving inflammatory disorders comprising fraction of Oenanthe javanica ethanol extract as effective component | |
KR102232817B1 (en) | Pharmaceutical composition for preventing or treating cancer, comprising a Senecio Rowleyanus Jacobs extract | |
TW200522973A (en) | Neutralization agent of vacuolization toxin | |
KR20190085459A (en) | Composition for preventing or treating cancer comprising codium extracts or fraction thereof, and trail protein | |
KR20040098839A (en) | EXTRACTS OF Lespedeza cuneate G. Don AND THEIR USES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007520020 Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005760105 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005760105 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11631655 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11631655 Country of ref document: US |